Crossmark Global Holdings Inc. Increases Stake in AbbVie Inc. $ABBV

Crossmark Global Holdings Inc. grew its stake in AbbVie Inc. (NYSE:ABBV) by 42.4% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 64,932 shares of the company’s stock after purchasing an additional 19,340 shares during the period. Crossmark Global Holdings Inc.’s holdings in AbbVie were worth $15,034,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Evolution Wealth Management Inc. acquired a new stake in AbbVie during the second quarter valued at $26,000. Caitlin John LLC purchased a new stake in shares of AbbVie during the 3rd quarter worth about $33,000. Spurstone Advisory Services LLC acquired a new stake in shares of AbbVie during the 2nd quarter valued at about $28,000. Redmont Wealth Advisors LLC purchased a new position in shares of AbbVie in the 3rd quarter valued at about $41,000. Finally, Financial Gravity Companies Inc. acquired a new position in AbbVie in the 2nd quarter worth about $36,000. Institutional investors and hedge funds own 70.23% of the company’s stock.

Insider Activity

In related news, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the sale, the executive vice president owned 38,137 shares of the company’s stock, valued at approximately $8,771,510. This trade represents a 36.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.25% of the stock is owned by company insiders.

AbbVie Stock Down 1.7%

Shares of ABBV opened at $232.07 on Friday. AbbVie Inc. has a 52-week low of $164.39 and a 52-week high of $244.81. The stock has a market cap of $410.34 billion, a PE ratio of 98.33, a price-to-earnings-growth ratio of 0.82 and a beta of 0.34. The firm’s fifty day moving average is $224.72 and its two-hundred day moving average is $223.80.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, topping the consensus estimate of $2.65 by $0.06. The firm had revenue of $16.62 billion for the quarter, compared to the consensus estimate of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The company’s revenue for the quarter was up 10.0% on a year-over-year basis. During the same period last year, the firm posted $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, research analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 3.0%. The ex-dividend date is Wednesday, April 15th. AbbVie’s payout ratio is currently 293.22%.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Positive Phase 3 AFFIRM results for risankizumab in moderately‑to‑severely active Crohn’s disease — higher clinical remission and endoscopic response vs. placebo, which could expand label/market for a high‑value asset and support longer‑term revenue growth. Assessing AbbVie (ABBV) Valuation After Positive Phase 3 Crohn’s Disease Trial Results
• Positive Sentiment: AbbVie advances venetoclax into a Phase 2 program for rare blood cancers in Japan — expands oncology pipeline and potential incremental revenue streams if studies read out positively. AbbVie Advances Venetoclax Into Rare Blood Cancers With New Phase 2 Study
• Positive Sentiment: Allergan Aesthetics (an AbbVie unit) highlights Medical Weight Loss data showing shifting patient demand — supports the aesthetics growth narrative and diversification beyond immunology. ALLERGAN AESTHETICS HIGHLIGHTS MEDICAL WEIGHT LOSS (MWL) DATA AND THE CHANGING PROFILE OF PATIENTS
• Positive Sentiment: Operationally constructive: AbbVie expansion reported to boost supply resilience for immunology medicines — lowers execution/supply risk for key franchises. AbbVie (NYSE:ABBV) Expansion Boosts Supply Resilience For Immunology Medicines
• Positive Sentiment: Third‑party bullish coverage and cash‑flow narratives emphasize AbbVie’s strong free cash flow and dividend profile — supportive for income investors and valuation stability. AbbVie: The Only Big Pharma Stock I’d Consider a Buy‑and‑Never‑Sell
• Neutral Sentiment: Corporate presentation/transcript from AbbVie at TD Cowen — may contain incremental detail on strategy and pipeline but no singular catalyst reported in the summary. AbbVie Inc. (ABBV) Presents at TD Cowen 46th Annual Health Care Conference Transcript
• Neutral Sentiment: Technical/market commentary notes the stock stabilizing near ~$233 while testing resistance levels — useful for short‑term traders but not a fundamental driver. AbbVie: Stabilizes Near $233 While Testing Resistance
• Neutral Sentiment: Market note reporting AbbVie’s share move relative to the broader market — descriptive of price action rather than a new driver. AbbVie (ABBV) Suffers a Larger Drop Than the General Market: Key Insights
• Negative Sentiment: Large senior notes offering (~$7.5–$8.0B) announced/completed — raises concerns about increased leverage and near‑term debt servicing; markets often view sizable debt raises as a near‑term negative for equity. AbbVie Completes $8 Billion Senior Notes Financing Offering AbbVie Announces $7.5 Billion Senior Notes Offering
• Negative Sentiment: AbbVie lost a bid to block Tennessee’s 340B law — regulatory/policy risk that could pressure pricing/reimbursements and is a negative for revenue in affected programs. AbbVie loses bid to block Tennessee 340B law

Analyst Upgrades and Downgrades

ABBV has been the topic of several research analyst reports. Royal Bank Of Canada initiated coverage on AbbVie in a report on Tuesday, February 24th. They issued an “outperform” rating and a $260.00 price objective on the stock. Morgan Stanley lifted their price target on shares of AbbVie from $269.00 to $270.00 and gave the company an “overweight” rating in a research note on Thursday, February 5th. Citigroup reduced their price objective on shares of AbbVie from $235.00 to $230.00 and set a “neutral” rating for the company in a research report on Tuesday, January 27th. Berenberg Bank set a $275.00 price objective on shares of AbbVie in a report on Tuesday, January 20th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of AbbVie in a research note on Wednesday, January 21st. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $253.15.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.